What is the purpose of this trial?
The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6 inhibitor.
Ages: 18 years and older
Dates: 02/02/2017 - 01/01/2018
Last Updated: 02/09/2017
Study HIC#: 1608018178